Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data.

Pre marketing clinical trials are clinical trials designed to obtain information about the effectiveness and safety of a new drug.

AltruBio Inc. starts Phase 2a trial for its drug ALTB-268 in ulcerative colitis patients with the first participant enrolled.

PARP inhibitors are drugs targeting the DNA-repairing enzyme PARP1, used in treating ovarian and breast cancer. With ongoing R&D, their future use is expected to expand.

Vittoria Biotherapeutics Reveals US FDA Approval of Investigational New Drug Submission for VIPER-101 to Address T-Cell Lymphoma Therapy.

Determining the causal relationship between a drug and a suspected adverse reaction is sometimes very difficult and takes a long time.

Bio-Thera Solutions, Ltd has made public the approval of their product Avzivi® (bevacizumab-tnjn) by the United States Food and Drug Administration.

Plasminogen activators inhibitors are substances that regulate clotting by inhibiting enzymes that break down blood clots.

ExeGi Pharma, a biopharmaceutical pioneer in live biotherapeutics, has commenced patient enrollment for its pivotal PROF Trial to test EXE-346, a new treatment targeting frequent bowel movements post ileal pouch-anal anastomosis surgery.

After the "Thalidomide Incident" in the 1960s, regulatory authorities in many countries established voluntary reporting systems for adverse drug reactions to collect adverse drug reactions.

Pfizer Inc. has released an announcement that the European Commission has provided a conditional marketing approval for their product, ELREXFIO (elranatamab).

As an important regulator of cAMP signal transduction, the PDE4 family has become a research hotspot for various diseases in recent years.